Cargando…
Determinants of Quality of Life in Myasthenia Gravis Patients
Background: Although approximately half of myasthenia gravis (MG) patents achieve remission, for the remaining group MG is often a life-long disease. Better understanding of the determinants of Quality of Life (QoL) in MG is needed to optimize treatment goals in chronic cases. Materials and Methods:...
Autores principales: | Szczudlik, Piotr, Sobieszczuk, Ewa, Szyluk, Beata, Lipowska, Marta, Kubiszewska, Justyna, Kostera-Pruszczyk, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538807/ https://www.ncbi.nlm.nih.gov/pubmed/33071942 http://dx.doi.org/10.3389/fneur.2020.553626 |
Ejemplares similares
-
Lower BAFF Levels in Myasthenic Patients Treated with Glucocorticoids
por: Sobieszczuk, Ewa, et al.
Publicado: (2021) -
Prevalence and impact of autoimmune thyroid disease on myasthenia gravis course
por: Kubiszewska, Justyna, et al.
Publicado: (2016) -
Afterdischarges in Myasthenia Gravis
por: Yang, Li, et al.
Publicado: (2021) -
Corrigendum: Pediatric CIDP: Diagnosis and Management. A Single-Center Experience
por: Łukawska, Małgorzata, et al.
Publicado: (2022) -
Pediatric CIDP: Diagnosis and Management. A Single-Center Experience
por: Łukawska, Małgorzata, et al.
Publicado: (2021)